標準治療で改善しない膠芽腫—標準治療と個別化治療

Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities

膠芽腫の標準治療は最大限の外科的摘出と，術後のテモゾロミド投与ならびに放射線治療だが，いまなお致死的な悪性脳腫瘍である。標準治療に加えて，ベバシズマブのほか，光線力学的療法，BCNU waferなどの局所追加療法や，交流電場腫瘍治療システムやゲノム医療といった限られた治療モダリティの特性を理解すると同時に，個々の患者の状態によってこれらを適切に組み合わせ，最大限に活用し，この難治性疾患の治療にあたる必要がある。

Abstract

The standard treatment for glioblastoma is maximal surgical resection followed by postoperative temozolomide administration combined with radiation therapy. Although treatment outcomes have improved in recent years, glioblastoma remains a fatal malignant brain tumor. In addition to standard treatment, it is important to understand the characteristics of additional therapies or limited therapeutic modalities, such as bevacizumab, photodynamic therapy, BCNU wafers, tumor treating fields, and genomic medicine. Furthermore, combination therapy should be applied, depending on the individual patient's condition, to treat this intractable disease.